If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
135
results.
Updated on
14/03/2025 [07:39:00]
Results 75 to 100 of 135
Absstract of: AU2023249247A1
Methods to alleviate or treat Alzheimer's Disease or a neurological disorder or disorder, or to alleviate the symptoms of each thereof are provided, the methods comprising administering an effective amount of (HSPC) or a population of HSPCs to the subject, that are optionally gene-corrected prior to administration and that will differentiate on healthy microglia cells in the brain. The cells are capable of decreasing amyloid plaques and inflammation.
Absstract of: EP4506012A1
The present invention relates to the therapeutic use of extract from rabbit skin inflamed by vaccinia virus. More specifically, the present invention relates to the use of extract from rabbit skin inflamed by vaccinia virus for treating Alzheimer's disease. In addition, the present invention relates to the use of extract from rabbit skin inflamed by vaccinia virus for protecting neurological function of the brain or alleviating damage to neurological function of the brain in a patient suffering from Alzheimer's disease. In addition, the extract from rabbit skin inflamed by vaccinia virus can be Lepalvir.
Absstract of: EP4506013A1
The use of extract from rabbit skin inflamed by vaccinia virus for treating Parkinson's disease or restoring neurological function of the brain or alleviating damage to neurological function of the brain in a patient suffering from Parkinson's disease is provided. The extract from rabbit skin inflamed by vaccinia virus can be Lepalvir.
Absstract of: KR20250020867A
본 발명은 ML324를 유효성분으로 포함하는 알츠하이머 치매 예방 또는 치료용 조성물에 관한 것으로, 본 발명의 ML324는 인지 기능 손상을 차단하고 Aβ 침전물을 감소시키며, 나아가 뇌 염증을 효과적으로 감소시키므로, 이를 포함하는 약학적 조성물은 산업에 유용하게 활용될 수 있다.
Absstract of: US2025042865A1
ZnCl2 co-crystal of racemic-(±)-blarcamesine hydrochloride of formula 2a, ZnCl2 co-crystal of (S)-(−)-blarcamesine hydrochloride of formula 2b and ZnCl2 co-crystal of (R)-(+)-blarcamesine hydrochloride of formula 2c, processes for preparation thereof and pharmaceutical preparation thereof and methods of treating neurodegenerative, neurodevelopmental diseases such as Alzheimer's disease, Parkinson's disease dementia and/or Rett syndrome.
Absstract of: US2025042873A1
Compounds and methods for treating proteotoxicity-associate diseases, including neurodegenerative diseases, such as Alzheimer's disease (AD), frontotemporal dementia (FTD), and amyotrophic lateral sclerosis (ALS), are disclosed.
Absstract of: US2025041247A1
The present disclosure provides methods, uses, kits, and compositions comprising a compound of Formula (I), and either a second compound of Formula (I) or a compound of Formula (II). In one aspect, the methods are for treating a neurological disease associated with repeat expansions and/or RAN protein accumulation, reducing the level of one or more repeat associated non-AUG (RAN) proteins, and reducing the accumulation of RAN proteins in a subject and/or biological sample. Exemplary diseases associated with repeat expansions include, but are not limited to, amyotrophic lateral sclerosis (ALS), frontotemporal dementia, myotonic dystrophy type 1, myotonic dystrophy type 2, spinocerebellar ataxia, Alzheimer's disease, Huntington's disease, Fragile X Tremor Ataxia Syndrome, and Fragile XE syndrome.
Absstract of: US2025041317A1
Provided herein are methods for improving working memory and/or executive function in a subject suffering from Huntington's Disease, comprising administering to the subject SAGE-718, an investigational positive allosteric modulator of the NMDA receptor.
Absstract of: US2025041248A1
Provided herein are methods for treating Alzheimer's disease using increased dosages amounts of ALZ-801.
Absstract of: WO2025030155A1
Among other things, the present disclosure provides various technologies including chirally controlled oligonucleotide compositions and technologies tor manufacturing and using such oligonucleotide compositions. In some embodiments, the present disclosure provides technologies useful for allele -specific knockdown of mutant Huntingtin transcripts. In some embodiments, tire present disclosure provides technologies useful for reducing the expression, level, amount, and/or activity of mutant Huntingtin transcripts or products thereof. In some embodiments, the present disclosure provides methods for treating Huntington's disease.
Absstract of: US2025042979A1
Methods of treating Alzheimer's Disease (AD) in patients suffering from early AD, including amyloid positive patients, ApoE4 positive patients, and patients suffering from prodromal or mild AD are provided.
Absstract of: MX2024011665A
The present invention relates to therapeutical uses of non-classical human major histocompatibility complex (MHC) molecules (also named MHC class lb molecules) in combination with peptide antigens for the treatment of Parkinson's disease. The invention more specifically relates to recombinant polypeptides comprising peptide antigens and one or more domains of a non-classical MHC class lb molecule. The invention also relates to methods of producing such recombinant polypeptides, pharmaceutical compositions comprising the same, as well as their uses for treating Parkinson's disease.
Absstract of: WO2023187838A1
Phialomustin B (1) for treatment of Parkinson's disease (PD) and Amyotrophic lateral sclerosis (ALS) The present invention provides Phialomustin B (1) a natural product isolated from the endophytic fungus Phialophora Mustea from the Corms of Crocus sativus. The present invention describes therapeutic potential of Phialomustin B (1) as Keap1 inhibitor for Parkinson's disease (PD) and SOD-1 modulator for Amyotrophic lateral sclerosis (ALS). The present invention also provides a pharmaceutical composition comprising an effective amount of Phialomustin B (1) of Formula I.
Absstract of: WO2023187091A1
The present invention relates to a sphingosine-1-phosphate receptor (S1PR) modulator for use in treating a patient suffering from Alzheimer's dementia.
Absstract of: EP4501336A1
The present invention relates to a pharmaceutical composition for preventing and treating a degenerative brain disease, specifically dementia, comprising an activated natural killer cell as an active ingredient. The pharmaceutical composition comprising a mouse-derived activated natural killer cell as an active ingredient, according to the present invention, regulates the activity of microglial cells and inhibits the deposition of amyloid β plaques. In addition, the pharmaceutical composition showed an excellent effect on cognitive function improvement in an animal model of dementia. Furthermore, when a human peripheral blood mononuclear cell-derived natural killer cell and a human induced pluripotent stem cell-derived natural killer cell were activated, it was confirmed that the expression of some genes involved in restoring the activity of microglial cells was similar to or higher than that of a mouse-derived activated natural killer cell. Therefore, the pharmaceutical composition of the present invention can be effectively used for preventing or treating a degenerative brain disease, such as dementia, Parkinson's disease, and Huntington's disease, and improving cognitive impairment.
Absstract of: AU2023240256A1
Aspects of the disclosure relate to compositions and methods useful for treating Parkinson's disease. In some embodiments, the disclosure provides a method for treating Parkinson's disease comprising administration of a viral vector comprising a GDNF nucleic acid sequence. In some embodiments, administration is locally to the subject putamen. In some embodiments, administration is systemically, e.g., via the viral vector comprising a modified viral capsid, such as for preferentially targeting cells in the CNS or PNS.
Absstract of: AU2023245460A1
Amyotrophic lateral sclerosis (ALS) is a debilitating and fatal neurodegenerative disease in humans. The underlying hallmarks of the disease involve lipid peroxidation (LPO) of polyunsaturated fatty acids (PUFAs) in the motor neurons. Central to this oxidative pathway is the presence of labile bis-allylic hydrogen atoms found in arachidonic acid, the dominant PUFA found in neurons. Disclosed are prophylactic methods for delaying the onset of the accelerated loss of functionality in patients suffering from ALS in humans. The methods comprise use of a deuterated arachidonic acid or a prodrug thereof.
Absstract of: KR20250017150A
본 발명은 파필로마바이러스 바이러스 유사입자 기반 항-아밀로이드 베타 알츠하이머병 백신에 관한 것으로서, 구체적으로, 본 발명은 사람유두종바이러스(Human Papillomavirus, HPV)의 바이러스 유사입자에 아밀로이드 베타 항원기를 탑재한 알츠하이머병 백신에 대한 것이다. 본 발명에 의하면 구조 특성 및 면역 특성이 우수한 HPV VLPs에 아밀로이드 베타 펩타이드 조각을 연결해 아밀로이드 베타에 대한 항체 유도 효과를 크게 향상시킬 수 있다. 또한, 본 발명에서 제조된 백신은 기존 VLPs 기반 알츠하이머병 백신보다 우수한 면역원성 및 양전율을 나타내는 것을 확인하였다.
Absstract of: AU2023313331A1
The present invention relates to a compound of general formula (I). The invention further relates to the compounds of the invention as neuroprotective and/or neurorestorative agents, in particular for use in the treatment of neurological disorders, such as e.g. central nervous system (CNS) diseases, Alzheimer's disease (AD), Parkinson's disease (RD), Huntington's disease (HD), amyotrophic lateral sclerosis (ALS), dementia, stroke, head trauma, brain tumor, pain and epilepsy. The compounds of the invention show GFR alpha 1-RET activity in a luciferase assay.
Absstract of: WO2025021237A1
The present invention relates to the use of bis(phenylmethylene)cycloalkanones and heterocyclic analogues thereof in human and veterinary medicine, for the treatment of diseases caused by the presence or elevated levels of metastable proteins in the cell, imbalances in protein homeostasis and proteotoxic stress, in general proteinopathy, in particular their use in the treatment of neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS), Parkinson's disease (PD), Alzheimer's disease (AD), Kennedy's disease (KD), Huntington's disease (HD), Creutzfeldt-Jakob disease (CJD), spinocerebellar ataxia (SCA), dentatorubral- pallidoluysian atrophy, transthyretin familial amyloid polyneuropathy, systemic amyloidosis, organ- confined amyloidosis, cystic fibrosis, and diabetes. Furthermore, the invention provides novel bis(phenylmethylene)cycloalkanones.
Absstract of: WO2025021908A1
The present invention relates to a composition comprising an estetrol component for use in the prevention and treatment of menopause-associated Alzheimer's disease symptoms. The composition described herein displays favorable properties when compared to existing estrogen-based compositions that aim to alleviate estrogen deficiency symptoms. Also described are related uses and methods of treatment comprising administration of the composition.
Absstract of: WO2025023339A1
The present invention relates to a use of a novel compound for preventing, alleviating, or treating Parkinson's disease, the novel compound exhibiting an effect of inhibiting synuclein aggregation in a Parkinson's disease (PD) mouse model. As a result of histological analysis, it was confirmed that the loss of dopaminergic neurons was blocked by treatment with the novel compound. Therefore, the novel compound can be effectively utilized in the development of a therapeutic agent for Parkinson's disease.
Absstract of: WO2025024285A1
Provided herein are compositions, systems, and methods comprising effector proteins for treating amyotrophic lateral sclerosis and Frontotemporal dementia. These effector proteins may be characterized as CRISPR-associated (Cas) proteins. Various compositions, systems, and methods of the present disclosure may leverage the activities of these effector proteins for the modification of the C9ORF72 gene.
Absstract of: WO2025023160A1
The present invention pertains to: a composition for use in the treatment or prevention of dementia such as Alzheimer's disease; and a method for treating or preventing dementia.
Nº publicación: WO2025024311A2 30/01/2025
Applicant:
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI [US]
THE UNIV OF NORTH CAROLINA AT CHAPEL HILL [US]
YALE UNIV [US]
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI,
THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL,
YALE UNIVERSITY
Absstract of: WO2025024311A2
Described is small molecule N-(l-isopropylpiperidin-4-yl)-6-methoxy-2-morpholino-7- (3-(pyrrolidin-l-yl)propoxy)quinolin-4-amine)) (MS 1262) that inhibits methyltransferases G9a/GLP. This inhibitor can be used for the treatment of patients with G9a/GLP related diseases such as Alzheimer's Disease and Prader-Willi Syndrome.
BOPI
Electronic site
